ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive
survivors

J 2021

ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors

HUBACEK, Jaroslav A.; Ladislav DUŠEK; Ondřej MÁJEK; Vaclav ADAMEK; Tereza CERVINKOVA et al.

Základní údaje

Originální název

ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors

Autoři

HUBACEK, Jaroslav A.; Ladislav DUŠEK; Ondřej MÁJEK ; Vaclav ADAMEK; Tereza CERVINKOVA; Dana DLOUHA a Vera ADAMKOVA

Vydání

Clinica Chimica Acta, AMSTERDAM, ELSEVIER SCIENCE BV, 2021, 0009-8981

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

20602 Medical laboratory technology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.315

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/21:00121855

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1016/j.cca.2021.04.024

UT WoS

000659205000008

EID Scopus

2-s2.0-85106338177

Klíčová slova anglicky

COVID-19; ACE; Polymorphism; Insertion; deletion

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 6. 2021 13:50, Mgr. Tereza Miškechová

Anotace

V originále

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread from China in 2019/ 2020 to all continents. Significant geographical and ethnic differences were described, and host genetic background seems to be important for the resistance to and mortality of COVID-19. Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism (rs4646994) is one of the candidates with the potential to affect infection symptoms and mortality. Methods: In our study, we successfully genotyped 408 SARS-CoV-2-positive COVID-19 survivors (163 asymptomatic and 245 symptomatic) and compared them with a population-based DNA bank of 2,559 subjects. Results: The frequency of ACE I/I homozygotes was significantly increased in COVID-19 patients compared with that in controls (26.2% vs. 21.2%; P = 0.02; OR [95% CI] = 1.55 [1.17-2.05]. Importantly, however, the difference was driven just by the symptomatic subjects (29.0% vs. 21.2% of the I/I homozygotes; P = 0.002; OR [95% CI] = 1.78 [1.22-2.60]). The genotype distribution of the ACE genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients (P = 0.76). Conclusions: We conclude that ACE I/D polymorphism could have the potential to predict the severity of COVID19, with I/I homozygotes being at increased risk of symptomatic COVID-19.

Citovat

HUBACEK, Jaroslav A.; Ladislav DUŠEK; Ondřej MÁJEK; Vaclav ADAMEK; Tereza CERVINKOVA; Dana DLOUHA a Vera ADAMKOVA. ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors. Clinica Chimica Acta. AMSTERDAM: ELSEVIER SCIENCE BV, 2021, roč. 519, AUG 2021, s. 206-209. ISSN 0009-8981. Dostupné z: https://doi.org/10.1016/j.cca.2021.04.024.

@article{1779177,
   author = {Hubacek, Jaroslav A. and Dušek, Ladislav and Májek, Ondřej and Adamek, Vaclav and Cervinkova, Tereza and Dlouha, Dana and Adamkova, Vera},
   article_location = {AMSTERDAM},
   article_number = {AUG 2021},
   doi = {https://doi.org/10.1016/j.cca.2021.04.024},
   keywords = {COVID-19; ACE; Polymorphism; Insertion; deletion},
   language = {eng},
   issn = {0009-8981},
   journal = {Clinica Chimica Acta},
   title = {ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors},
   url = {https://www.sciencedirect.com/science/article/pii/S0009898121001492?via%3Dihub},
   volume = {519},
   year = {2021}
}

TY  - JOUR
ID  - 1779177
AU  - Hubacek, Jaroslav A. - Dušek, Ladislav - Májek, Ondřej - Adamek, Vaclav - Cervinkova, Tereza - Dlouha, Dana - Adamkova, Vera
PY  - 2021
TI  - ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors
JF  - Clinica Chimica Acta
VL  - 519
IS  - AUG 2021
SP  - 206-209
EP  - 206-209
PB  - ELSEVIER SCIENCE BV
SN  - 00098981
KW  - COVID-19
KW  - ACE
KW  - Polymorphism
KW  - Insertion
KW  - deletion
UR  - https://www.sciencedirect.com/science/article/pii/S0009898121001492?via%3Dihub
N2  - Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread from China in 2019/ 2020 to all continents. Significant geographical and ethnic differences were described, and host genetic background seems to be important for the resistance to and mortality of COVID-19. Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism (rs4646994) is one of the candidates with the potential to affect infection symptoms and mortality. Methods: In our study, we successfully genotyped 408 SARS-CoV-2-positive COVID-19 survivors (163 asymptomatic and 245 symptomatic) and compared them with a population-based DNA bank of 2,559 subjects. Results: The frequency of ACE I/I homozygotes was significantly increased in COVID-19 patients compared with that in controls (26.2% vs. 21.2%; P = 0.02; OR [95% CI] = 1.55 [1.17-2.05]. Importantly, however, the difference was driven just by the symptomatic subjects (29.0% vs. 21.2% of the I/I homozygotes; P = 0.002; OR [95% CI] = 1.78 [1.22-2.60]). The genotype distribution of the ACE genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients (P = 0.76). Conclusions: We conclude that ACE I/D polymorphism could have the potential to predict the severity of COVID19, with I/I homozygotes being at increased risk of symptomatic COVID-19.
ER  -

HUBACEK, Jaroslav A.; Ladislav DUŠEK; Ondřej MÁJEK; Vaclav ADAMEK; Tereza CERVINKOVA; Dana DLOUHA a Vera ADAMKOVA. ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors. \textit{Clinica Chimica Acta}. AMSTERDAM: ELSEVIER SCIENCE BV, 2021, roč.~519, AUG 2021, s.~206-209. ISSN~0009-8981. Dostupné z: https://doi.org/10.1016/j.cca.2021.04.024.

Přehled o publikaci